CD274 and esophageal squamous cell carcinoma: Thus, based on those results, nivolumab received the European commission approval for ESCC in November 2020 [27]; it is considered the new standard of care in the second-line treatment for metastatic ESCC after a fluoropyrimidine-based chemotherapy, regardless of PD-L1 status.